<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922945</url>
  </required_header>
  <id_info>
    <org_study_id>OB-403</org_study_id>
    <nct_id>NCT03922945</nct_id>
  </id_info>
  <brief_title>A Phase IV Safety and Efficacy of VI-0521 in Obese Adolescents</brief_title>
  <official_title>A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Determine the Safety and Efficacy of VI-0521 in Obese Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess weight loss efficacy, as determined by changes in
      body mass index (BMI), and safety of VI-0521 (Qsymia®) or placebo, taken for 56 weeks
      accompanied by a lifestyle modification program in obese adolescents age 12-16 years.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean % change in body mass index (BMI)</measure>
    <time_frame>Baseline to Week 56</time_frame>
    <description>Mean % change in BMI from Baseline to Week 56</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving at least 5% BMI reduction at Week 56</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving at least 10% BMI reduction at Week 56</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving at least 15% BMI reduction at Week 56</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference at Week 56</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Whole Body Insulin Sensitivity Index at Week 56</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin at Week 56</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglycerides at Week 56</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL-C (High-Density Lipoprotein Cholesterol) at Week 56</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adolescent Obesity</condition>
  <condition>Obesity in Adolescence</condition>
  <condition>Adolescent Overweight</condition>
  <arm_group>
    <arm_group_label>VI-0521 Mid Dose (Phentermine 7.5 mg +Topiramate 46 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-56: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-12: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Weeks 13-14: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 15-56: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo oral capsule, once daily for up to 56 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521 oral capsule</intervention_name>
    <description>Phentermine/Topiramate</description>
    <arm_group_label>VI-0521 Mid Dose (Phentermine 7.5 mg +Topiramate 46 mg)</arm_group_label>
    <arm_group_label>VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)</arm_group_label>
    <other_name>Qsymia</other_name>
    <other_name>Phentermine and topiramate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Inactive drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 12 years and &lt; 17 years;

          -  BMI ≥ the 95th percentile, with documented history of failure to lose sufficient
             weight or failure to maintain weight loss in a lifestyle modification program;

          -  If female, must be using adequate contraception, defined as double barrier methods,
             stable hormonal contraception plus single barrier method, tubal ligation, or
             abstinence.

        Exclusion Criteria:

          -  Type 1 diabetes;

          -  Congenital heart disease; clinically significant ECG abnormality;

          -  Clinically significant physical exam, vital signs, or laboratory abnormality;
             clinically significant hepatic or renal disease;

          -  Estimated Glomerular Filtration Rate (GFR; Schwartz formula) &lt; 60 mL/minute;

          -  Clinically significant thyroid dysfunction as evidenced by signs, symptoms, or TSH &gt;
             1.5 x Upper Limit of Normal;

          -  Obesity of known genetic or endocrine origin;

          -  History of bipolar disorder or psychosis, depression of moderate or greater severity,
             or presence or history of suicidal behavior or active suicidal ideation;

          -  Recent weight instability, or prior bariatric surgery;

          -  History of glaucoma or increased intraocular pressure;

          -  Current smoker or smoking cessation within 3 months of screening;

          -  Currently taking or plan on taking any of following medications during the study:

               -  Anticonvulsants used for treatment of seizure disorder, including barbiturates,
                  benzodiazepines, GABA analogues, hydantoins, phenyltriazines, succinimides, and
                  other agents (valproic acid and its derivatives, carbamazepine and its
                  derivatives, zonisamide, and felbamate);

               -  Tricyclic antidepressants, MAOIs, lithium, levodopa, and dopamine receptor
                  agonists;

               -  Carbonic anhydrase inhibitors;

               -  Insulin, SFUs, GLP-1 agonists, SGLT-1, and SGLT-2 inhibitors;

               -  Chronic systemic steroids (i.e. glucocorticoids, anabolic steroids) other than
                  oral contraceptives;

               -  Treatment for hyperactivity disorder; or

               -  Over the counter, prescription medications, herbal agents and dietary supplements
                  used with the intention to lose body weight.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Intend Research, LLC</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>weight loss</keyword>
  <keyword>obesity</keyword>
  <keyword>weight control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

